Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis

BACKGROUND: Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction. OBJECTIVES: Objectives are to evaluate the efficacy and safety of liraglutide 3.0 mg in patients with overweight and obesity irrespective of diabetic status. METHODS: We conducted an electronic database sea...

Descripción completa

Detalles Bibliográficos
Autores principales: Konwar, Mahanjit, Bose, Debdipta, Jaiswal, Sanjeet Kumar, Maurya, Mitesh kumar, Ravi, Renju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325632/
https://www.ncbi.nlm.nih.gov/pubmed/35936066
http://dx.doi.org/10.1155/2022/1201977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325632/
https://www.ncbi.nlm.nih.gov/pubmed/35936066
http://dx.doi.org/10.1155/2022/1201977

Ejemplares similares